Treatment by self-medication: a consistently growing trend. Patients suffering from diabetes, rheumatoid arthritis or multiple sclerosis increasingly use pens or autoinjectors. Ease and safety of handling these devices are particularly important to them. For pharmaceutical manufacturers, the protection of patients against fake medicines and security of the supply chain are additionally of major importance. The EU Falsified Medicines Directive, besides serialization, addresses tamper protection of secondary packaging, however without considering first-opening indication for primary containers or devices. Schreiner MediPharm’s novel NFC-enabled autoinjector-Label for digital tamper evidence closes this risk gap.
The new Autoinjector-Label is both user-friendly and safe: It wraps around the autoinjector including the cap and has an integrated NFC chip that can be read very easily via a smartphone app. Before opening the cap for the first time, the
patient checks if the product is an original and receives respective confirmation. After opening the cap and label, and subsequently reading the NFC chip once more, a warning will immediately appear.
This warning shows that the product has previously been opened and indicates that it may have been tampered with. Thus, patients are able to easily and quickly check the intactness of their injection aids anywhere, anytime—and above all, can be certain to have received a safe medicine.
The integrated NFC chip has even more capabilities:
To optimally support patients during self-medication, pharmaceutical manufacturers are able to include additional interactive applications such as product information, demo videos or special apps. Additionally, integrated geo-tracking makes it possible to detect potential gray market activities in local markets. The digital Autoinjector-Label for NFC-based tamper evidence can easily be adapted to existing label designs and does not affect the normal application by the patient.